PRELIMINARY RESULTS OF THE PHASE 2 STUDY OF ZANUBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B‐CELL MALIGNANCIES INTOLERANT TO IBRUTINIB AND/OR ACALABRUTINIB. (17th June 2021)

• Record Type: Journal Article
• Authors: Shadman, M.; Sharman, J. P.; Levy, M. Y.; Porter, R.; Zafar, S. F.; Burke, J. M.; Chaudhry, A.; Freeman, B.; Misleh, J.; Yimer, H. A.; Cultrera, J. L.; Guthrie, T. H.; Kingsley, E.; Rao, S. S.; Chen, D. Y.; Zhang, X.; Idoine, A.; Cohen, A.; Feng, S.; Huang, J.; Flinn, I.
• Is Part Of: Hematological oncology. Volume 39(2021)Supplement 2
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-06-17
• Subjects: Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.42_2880
• Languages: English
• ISSNs: 0278-0232